- Mainz Biomed announced **positive topline results** from a feasibility study for a non-invasive blood-based screening test for the early detection of pancreatic cancer.  **[1874252_660ea921d0724a50846c13548bf111b9_0]** 
- The leading biomarker panel achieved **100% sensitivity and 95% specificity** in a 30-subject cohort, successfully distinguishing pancreatic cancer patients from healthy controls.  **[1874252_660ea921d0724a50846c13548bf111b9_0]** 
- The algorithm developed by Liquid Biosciences also successfully detected precancerous lesions, opening the door for earlier monitoring and intervention.  **[1874252_660ea921d0724a50846c13548bf111b9_0]** 
- Following these results, Mainz Biomed plans a larger clinical study to finalize biomarker selection and a subsequent validation study, which could lead to a future submission to the U.S. Food and Drug Administration (FDA).  **[1874252_660ea921d0724a50846c13548bf111b9_1]**

Mainz Biomed Reports Positive Feasibility Study Results for Pancreatic Cancer Test

- Mainz Biomed (NASDAQ:MYNZ) will participate in the World Endoscopy Organization's (WEO) Colorectal Cancer (CRC) Screening Committee Plenary Meeting on **October 3rd, 2025**, in Berlin, Germany.  **[1874252_8b94571082654f22a85225b9745c5ff0_0]** 
- Dr. Lena Krammes will present clinical data from the 2024 eAArly DETECT study, showcasing the potential of stool RNA testing to identify colorectal cancer and precancerous lesions.  **[1874252_8b94571082654f22a85225b9745c5ff0_0]** 
- Key findings from the study include **97% sensitivity and 97% specificity** for detecting colorectal cancer, **82% sensitivity** for advanced adenomas, and **100% detection** of advanced adenomas with high-grade dysplasia.  **[1874252_8b94571082654f22a85225b9745c5ff0_0]** 
- These results highlight the potential for RNA-based testing in both early detection and prevention of CRC, as Mainz Biomed continues its eAArly DETECT 2 clinical study in preparation for pivotal FDA study for US regulatory approval.  **[1874252_8b94571082654f22a85225b9745c5ff0_1]**

Mainz Biomed to Present RNA-based Colorectal Cancer Screening Data at WEO Meeting

- Mainz Biomed's **ColoAlert®** has received official registration with the Medicines and Healthcare products Regulatory Agency (MHRA), authorizing its marketing in the **United Kingdom**.  **[1874252_398a034167ac4cdab5b5d148758b0309_0]** 
- This approval enables the company's UK laboratory partner, EDX Medical Group plc, to provide the **DNA-based colorectal cancer screening test** across the UK.  **[1874252_398a034167ac4cdab5b5d148758b0309_0]** 
- The authorization supports the expansion of access to early cancer detection solutions and aims to complement the existing Bowel Cancer Screening Program in the UK, where colorectal cancer is the **fourth most common cancer**.  **[1874252_398a034167ac4cdab5b5d148758b0309_0]**

MAINZ BIOMED (MYNZ)